Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451636 | 0.86 | NPC1 (0.67) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL28918715 | 0.85 | NPC1 (0.54) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL376141 | 0.84 | LMNA (0.52) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL14397817 | 0.83 | REN (0.50) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL14397794 | 0.83 | NPC1 (0.50) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL14397790 | 0.79 | MEN1 (0.47) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL2931129 | 0.79 | ALDH1A1 (0.66) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL2902849 | 0.78 | NPC1 (0.62) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL2934724 | 0.78 | NPC1 (0.53) | NPC1RAB9AKMT2AMEN1TDP1 | |
| SCHEMBL1845917 | 0.77 | ALDH1A1 (0.51) | NPC1RAB9AALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239845-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | CONWAY ELIZABETH ANN | 2009-09-24 | — | — | US | disclosed |
| EP-1874303-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006114313-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239845-A1 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS | PTGER1, PTGDR, PTGIR | NPC1 3127/4885RAB9A 1948/4885KMT2A 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.